Skip to main content
Fig. 4 | Cell & Bioscience

Fig. 4

From: Selonsertib, a potential drug for liver failure therapy by rescuing the mitochondrial dysfunction of macrophage via ASK1–JNK–DRP1 pathway

Fig. 4

Selonsertib prevents LPS-primed JNK and DRP1 mitochondrial translocation and mitochondrial damage in macrophages. a, b Western blot analysis of p-JNK, JNK, p-DRP1 and DRP1 levels (a) and mitochondrial dynamics-related protein levels in primary hepatic macrophages isolated from different groups of LPS/GalN-injected mice. Two from 6 samples were shown in the blots. c Determination of mitochondrial oxidative stress in primary hepatic macrophages by using MitoSox. d Mitochondrial oxidative stress, mitochondrial membrane potential (Δψm), and mitochondrial permeability transition pore (mPTP) opening in normal cultured (NC) and LPS-primed RAW264.7 cells are shown by MitoSox (left), JC-1 (middle) and calcein staining (right), respectively. e, f Western blot analysis of p-JNK, JNK, p-DRP1 and DRP1 levels in the whole cell (e) and the mitochondrial fraction (f) of RAW264.7 cells. g TNF-α and IL-1α secretion levels from RAW264.7 cells after LPS exposure were measured by ELISA. Data are presented as the mean ± SD (n = 3). **P < 0.01; ***P < 0.001; NC normal control, SEL selonsertib (30 mg/kg for in vivo; 5 µM for in vitro)

Back to article page